The True Cost of an Open Director Level Role in Pharma

When a Director level role goes unfilled for three months inside a pharmaceutical company, it rarely shows up as a single line item on anyone's budget report. The costs are distributed, partially invisible, and almost never calculated in full. Which is exactly why so many organizations continue to underestimate the urgency of filling these roles — and continue to use the same sourcing approaches that are not working.

I want to walk through the actual math. Not the abstract version where someone says "the cost of a bad hire is two to three times salary." The real calculation, based on what I have watched happen inside life sciences organizations when a Director level seat sits empty for four, five, or six months.

By the time you finish reading this, the number is going to be bigger than you expected. And that changes the conversation about what it is worth to fill a role faster — and more precisely — from the very beginning.

The Starting Point Most Organizations Get Wrong

The instinct when a Director level role opens is to start from the compensation figure. If the role pays $220,000, the cost of vacancy is roughly $18,000 per month in deferred productivity. That feels manageable. That feels like something you can absorb for a quarter or two while you run a search.

But that calculation only captures the output that would have been generated by the person in the seat. It does not capture what happens to everyone around that empty seat.

Director level positions in pharma are not individual contributor roles. They carry functional accountability, they own decisions, they run meetings, they unblock work, and they absorb the organizational complexity that would otherwise fall on a VP or a C suite leader who has other things to do. When that role is empty, that accountability does not disappear. It redistributes.

The Full Cost Model

Here is how I think about the cost of an open Director level role across the most common expense categories. I am using a base salary of $220,000 as the baseline for this example, which sits around the market midpoint for a Director of Clinical Development, Regulatory Affairs, or Medical Affairs at a mid size biopharma in 2025.

That number — north of $400,000 for a six-month vacancy at the Director level — is not hypothetical. It is built from real conversations I have had with TA leaders and finance partners inside pharma organizations who have actually tried to quantify this. Some organizations come out lower. Some come out significantly higher depending on how program-critical the role is.

The Program Delay Multiplier

The line item that most organizations never fully calculate is delayed program milestones. This one is hard to quantify precisely, which is why it usually gets excluded from the analysis. But it is frequently the largest single cost in the entire model.

Consider a Director of Clinical Operations at a Phase III company. Their primary responsibility is managing the execution of a pivotal trial. If that seat sits empty for five months, one of a few things happens. Either a VP steps in and runs execution decisions that should never require VP level attention, or the program slows down as the team waits for decisions that need a functional leader, or a contractor is brought in at significant cost to hold the function temporarily.

In any of those scenarios, the downstream impact on program timeline is real. A one-month delay in a Phase III timeline costs most mid size pharma companies somewhere between $800,000 and $2,000,000 depending on the program, the indication, and where they are in the development calendar. That number dwarfs everything else in the cost model.

Now, not every Director level vacancy creates a program delay. But a meaningful percentage of them do, and the organizations that feel the urgency to move quickly are almost always the ones that have already experienced what a slow search costs them.

The Team Morale Cost That Nobody Writes Down

There is another cost that does not make it into any spreadsheet but shows up reliably in every organization where a leadership role sits open for too long. The team underneath that empty seat starts to look around.

When a Director role is vacant, the people who report into it — or who are peers of it — are doing more work for the same pay. They are making decisions above their level because there is nobody else to make them. They are absorbing the organizational stress of an undefined leadership structure. And they are watching how long the company takes to resolve the situation.

In my experience, a vacancy that exceeds four months at the Director level has a measurable impact on team stability. Not always. But often enough that I flag it explicitly in conversations with clients who have been sitting on an open search for a while without urgency.

• The strongest performer on the team is typically the first one to update their LinkedIn profile. They have the most options. They are absorbing the most extra work. And they have the clearest view of what the situation says about organizational decision making.
• The mid level contributors start to recalibrate their relationship with the organization. Not necessarily toward the door, but toward a more guarded version of engagement. They do their jobs. They stop going above and beyond.
• The hiring manager who owns the vacancy starts spending real time managing up the situation — explaining to their leadership why the role is still open — rather than running the actual function they were hired to run.

None of those dynamics are catastrophic individually. Together, over four or five months, they are the beginning of a team culture shift that takes twelve to eighteen months to reverse once the hire is finally made.

What This Means for How You Think About Search Fees

The most common objection I hear when a client is weighing a search fee — whether contingency or retained — is some version of "that feels like a lot of money." And I understand it. A placement fee in the range of $55,000 to $75,000 on a $220,000 Director level role is not a small number in isolation.

But in the context of a $400,000 vacancy cost over six months, the math changes completely. The question is not whether the fee is expensive. The question is whether a faster, more precise search — one that delivers a curated shortlist in 10 business days instead of posting a job and waiting — justifies that fee by compressing the vacancy timeline and reducing the probability of settling for an adequate candidate instead of an excellent one.

For almost every Director level role in life sciences, the answer is yes. The fee pays for itself many times over if it takes three months off the vacancy clock, and it pays for itself many more times over if it prevents a bad hire that needs to be unwound twelve months later.

The Bad Hire Calculation

I want to spend a moment on the bad hire scenario specifically, because it compounds every cost I have described above rather than resolving them.

When a Director level hire does not work out at 12 months — and in pharma, the rate of involuntary Director level separations within the first 18 months is higher than most organizations want to admit — the total cost is not just the vacancy cost on the back end of the failed hire. It includes everything that happened during those 12 months.

A Director who was a poor fit did not make the decisions a strong leader would have made. They absorbed organizational capital — management attention, team goodwill, onboarding investment — and returned less of it than they took. And then you are back at the beginning, except now the team has been through the experience of watching someone fail, and the organization has spent 12 months plus a full new search cycle to end up where it started.

This is why the quality of the sourcing model matters as much as the speed. The goal is not just to fill the seat faster. It is to fill it with someone who is genuinely right for the specific role, the specific team, and the specific stage of the organization — and who was carefully enough evaluated that the probability of that outcome is as high as it can be.

A Simpler Way to Frame the Decision

If you are a VP or Chief People Officer sitting on an open Director level search that has been running for more than 90 days without a viable finalist, here is the simplest way I know to frame the decision in front of you.

Every additional month of vacancy costs you somewhere between $50,000 and $100,000 in direct and indirect costs, not counting program delay risk. You have two choices. You can continue the approach that has gotten you to where you are and hope the next round of sourcing produces a different result. Or you can bring in a partner with a different sourcing model, accept that the fee is a line item in the cost of solving the problem, and compress the timeline to resolution.

The first option is free at the point of decision. The second option has a visible upfront cost. But the math on which one is actually more expensive is usually not close.